UNSPSC 51142401: Methysergide

This classification denotes a serotonin agonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier XZA9HY6Z98. European Medicines Agency schedules Methysergide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08880MIG. Methysergide generally arises in the molecular formula C21H27N3O2.

UNSPSC 51142401 Methysergide is a Commodity code that state and local governments use to procure specific pharmaceuticals and related health-system products, though recent solicitations under this code show broader pharmaceutical procurement activity rather than methysergide narrowly. State and local issuing bodies—including county health departments, state health and human services agencies, and cooperative purchasing alliances—use the code to source generic pharmaceuticals, over-the-counter products, and emergency-response medications through competitive bidding. The work solicited spans routine pharmaceutical supply contracts with established wholesaler relationships, emergency preparedness procurement for naloxone and drug deactivation systems, and exploratory requests for information on direct-to-manufacturer prescription programs designed to optimize costs and supply-chain efficiency across state and local health plans.

Recent activity concentrates in the Southeast and Upper Midwest. Seminole County, Florida issued IFB 60459723LAS in June 2026 to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, responses due July 26, 2023. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities including Oregon, with proposals due March 26, 2026. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, seeking vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels. Vendors must comply with drug supply chain security certifications, maintain relationships with authorized wholesalers, and meet federal manufacturing and safety standards; MMCAP requires $5 million in commercial general liability insurance and charges a 3 percent administrative fee on all contract purchases.